To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

3/21/2025, 5:32 PM

Summary of Bill HR 1843

Bill 119 HR 1843, also known as the "Increasing Transparency in Generic Drug Applications Act," aims to amend the Federal Food, Drug, and Cosmetic Act in order to enhance transparency in the process of approving generic drugs. The bill seeks to address concerns about the lack of transparency in the generic drug application process, which can lead to delays in bringing affordable medications to market.

Specifically, the bill includes provisions that require the Food and Drug Administration (FDA) to publish information about the status of generic drug applications on its website. This information would include the date of submission, the current status of the application, and any reasons for delays in approval. By making this information publicly available, the bill aims to increase accountability and transparency in the generic drug approval process.

Additionally, the bill includes provisions that require the FDA to provide more detailed explanations for any delays in approving generic drug applications. This would help to ensure that the FDA is held accountable for any delays and provide greater transparency for both drug manufacturers and consumers. Overall, Bill 119 HR 1843 seeks to improve the transparency of the generic drug approval process in order to facilitate the timely approval of affordable medications. By increasing transparency and accountability, the bill aims to ensure that generic drugs are brought to market in a timely manner, ultimately benefiting consumers by increasing access to affordable medications.

Read the Full Bill

Formatted TextPDFFormatted XML

Current Status of Bill HR 1843

Bill HR 1843 is currently in the status of Bill Introduced since March 5, 2025. Bill HR 1843 was introduced during Congress 119 and was introduced to the House on March 5, 2025.  Bill HR 1843's most recent activity was Referred to the House Committee on Energy and Commerce. as of March 5, 2025

Bipartisan Support of Bill HR 1843

Total Number of Sponsors
3
Democrat Sponsors
0
Republican Sponsors
3
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
1
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 1843

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 1843

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Start holding our government accountable!

Comments

Sponsors and Cosponsors of HR 1843

Neal P. Dunn
Neal P. Dunn
Florida(Republican)
Kevin Mullin
Kevin Mullin
California(Democrat)

Latest Bills

SAFE Lending Act of 2025
Bill HR 1658March 21, 2025
SAFE Lending Act of 2025
Bill S 780March 21, 2025
Bureau of Land Management Mineral Spacing Act
Bill S 722March 21, 2025
Sickle Cell Disease Comprehensive Care Act
Bill S 721March 21, 2025
GUARD Act
Bill HR 1866March 21, 2025
Affordable College Textbook Act
Bill S 740March 21, 2025
The Farmhouse-to-Workforce Housing Act of 2025
Bill S 686March 21, 2025
FIRE Cancer Act of 2025
Bill HR 1610March 21, 2025
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Bill HR 1843March 21, 2025
Bipartisan Health Care Act
Bill S 891March 21, 2025